Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | FLT3 | P36888 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8870075 | 0.91 | KMT2A (0.78) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL6866887 | 0.88 | PDGFRB (1.00) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL4263996 | 0.88 | PDGFRB (0.61) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL335655 | 0.87 | FLT3 (0.68) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL30189510 | 0.87 | FLT3 (0.68) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL2729934 | 0.87 | PDGFRB (0.79) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL1429381 | 0.85 | PDGFRB (0.77) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL1429500 | 0.85 | PDGFRB (0.77) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL1104006 | 0.85 | PDGFRB (0.77) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 | |
| SCHEMBL31361409 | 0.85 | PDGFRB (0.77) | PDGFRBPDGFRAKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 803 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874466-A | N, N-dimethylamide compound and synthesis method thereof | 海南大学 | 2025-04-25 | — | — | CN | claimed |
| WO-2024229094-A1 | METHODS FOR TREATING GASTROINTESTINAL INFLAMMATORY DISEASES USING ALPHA-KETOGLUTARATE (AKG) MODULATORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | WO | claimed |
| CN-109320448-A | The synthetic method of indole-2-carboxylic acid and its derivative | 重庆大学 | 2019-02-12 | — | — | CN | claimed |
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | claimed |
| US-20160368928-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | BIOVENTURES, LLC | 2016-12-22 | — | — | US | claimed |
| US-20150203508-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | BIOVENTURES, LLC | 2015-07-23 | — | — | US | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| EP-2205558-B1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | claimed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | claimed |
| EP-2205558-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | claimed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203508-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | CMBL, MGMT, MMAB | PDGFRB 512/4885PDGFRA 2792/4885KMT2A 484/4885 |
| US-20160368928-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | CMBL, MGMT, MMAB | PDGFRB 512/4885PDGFRA 2792/4885KMT2A 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.